- Currency Conversion is for Indicative purpose only. All orders are processed in US Dollars only.
- USD - US Dollar
- AUD — Australian Dollar
- BRL — Brazilian Real
- CNY — Yuan Renminbi
- EUR — Euro
- GBP — Pound Sterling
- INR — Indian Rupee
- JPY — Japanese Yen
- ZAR — South African Rand
- The Price Conversion is only for the Indicative purpose.
- USD — US Dollar
- AUD — Australian Dollar
- BRL — Brazilian Real
- CNY — Yuan Renminbi
- EUR — Euro
- GBP — Pound Sterling
- INR — Indian Rupee
- JPY — Japanese Yen
- ZAR — South African Rand
-
Product Insights
Product Insights Hypoglycemia – Drugs In Development, 2023 Hypoglycemia – Drugs In Development, 2023
$2,000 | January 2024 Global Markets Direct’s, ‘Hypoglycemia - Drugs In Development, 2023’, provides an overview of the Hypoglycemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hypoglycemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Product Insights Type 1 Diabetes (Juvenile Diabetes) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Type 1 Diabetes (Juvenile Diabetes) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
$2,500 | October 2022 Type 1 Diabetes Pipeline Drugs Market Report Overview Type 1 diabetes (T1D) occurs when the body’s immune system attacks and destroys the insulin-producing cells in the pancreas. The signs and symptoms of type 1 diabetes include increased thirst and frequent urination, extreme hunger, weight loss, fatigue, and irritability or unusual behavior. The Type 1 Diabetes pipeline drugs market research report provides comprehensive information on the therapeutics under development for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders), complete with analysis by...
-
Product Insights
Product Insights Hypoglycemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Hypoglycemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
$2,000 | March 2022 Hypoglycemia is a condition characterized by an abnormally low level of blood sugar (glucose). Symptoms of hypoglycemia include tachycardia, anxiety, shaking, irritability, feelings of hunger, weakness, tiredness, dizziness, headache, confusion, and trouble concentrating. Risk factors include drug or alcohol consumption, older age, longer duration of diabetes, renal disease, peripheral neuropathy, obesity, and cognitive dysfunction. The Hypoglycemia drugs in development market research report provide comprehensive information on the therapeutics under development for Hypoglycemia, complete with analysis by stage of development, drug...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.